Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | STAB | Common Stock, par value $0.005 per share | Award | $0 | +102K | $0.00 | 102K | Jul 27, 2021 | Direct | F1 |
Id | Content |
---|---|
F1 | Shares received pursuant to an Agreement and Plan of Merger ("merger agreement"), entered into by Cytocom Inc. ("Old Cytocom") and Cleveland BioLabs, Inc ("New Cytocom" or "Issuer"). Per the "merger agreement", each share of Old Cytocom (i) common stock, (ii) preferred stock that was not converted into Old Cytocom common stock immediately prior to the effective time of the Merger, and (iii) each vested restricted stock unit of Old Cytocom (excluding, in each case, dissenting shares and shares held in treasury) converted into the right to receive a number of shares of New Cytocom common stock based on an exchange formula set forth in the merger agreement (which we refer to as the "merger consideration"). |